V-Bio Ventures highlights investment gap in women's health treatments

• Women's health analysis identifies unmet demand for menopause treatments, calling for investment in research, diagnostics and alternatives to hormone replacement therapy.
• Only 15.6% of symptomatic US women ages 40–60 used prescription treatments in 2025, despite nearly half reporting menopause symptoms.
• Menopause symptoms cost the US an estimated US$1.8 billion annually in lost work time; including medical costs, the total reaches US$26.6 billion.
• The FDA removed menopause hormone therapy black box warnings in November 2025, but treatment hesitancy remains a barrier to uptake.
• Limited treatment alternatives leave persistent symptoms even among treated women, underscoring the need for better clinical trials and new therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. V-Bio Ventures published the original content used to generate this news brief on October 26, 2026, and is solely responsible for the information contained therein.